In conclusion, this was a real-world study regarding neoadjuvant-targeting therapy in HER2+ breast cancer in Taiwanese women, focusing especially on the efficacy of neoadjuvant chemotherapy combined with dual-targeting therapy. Here, ERBB2 is linked to breast carcinoma.